# US 2023/0406957 A1 · Dosing regimens for use with pcsk9 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406957 A1
- Document ID: US20230406957A1
- Status: Published application
- Kind: A1
- Application number: 18/301,638
- Filed: 2023-04-17
- Published: 2023-12-21
- Earliest claimed: 2013-11-12
- Assignees: Sanofi Biotechnology; Regeneron Pharmaceuticals, Inc.
- Applicants: Sanofi Biotechnology; Regeneron Pharmaceuticals, Inc.
- Inventors: Marie Baccara-Dinet; Laurence Bessac; Corinne Hanotin; Robert C. Pordy; William J. Sasiela; Jacques Rey
- Web page: https://patentgrep.com/patent/US20230406957A1

## CPC

- C07K 16/40: against enzymes
- A61P 3/06: Antihyperlipidemics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods for treating a PCSK9-mediated disease or a PCSK9-mediated condition. Specifically, the invention relates to methods comprising the administration of a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody or antigen binding protein, in the absence of a statin, to a subject in need thereof.

## Claims

### Claim at position 1

1-78. (canceled)

### Claim 79

A method for reducing low-density lipoprotein cholesterol (LDL-C) in a subject in need thereof, the method comprising:
(a) selecting a subject with primary hypercholesterolemia who is not taking a statin; and
(b) administering to the subject a pharmaceutical composition comprising an anti-proprotein convertase subtilisin/kexin type 9 (anti-PCSK9) antibody or antigen-binding fragment thereof at a dose of about 300 mg every 4 weeks for at least 3 doses in the absence of a concomitant statin therapy, wherein the antibody or antigen-binding fragment thereof comprises the heavy and light chain complementarity determining regions (CDRs) of a heavy chain variable region/light chain variable region (HCVR/LCVR) amino acid sequence pair of SEQ ID NOs: 1/6,
thereby reducing the LDL-C in the subject.

### Claim 80 (depends on 79)

The method of claim 79, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs:2, 3, 4, 7, 8, and 10.

### Claim 81 (depends on 80)

The method of claim 80, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:6.

### Claim 82 (depends on 79)

The method of claim 79, wherein the subject is on a non-statin lipid-lowering agent before and/or during administration of the antibody or antigen-binding protein.

### Claim 83 (depends on 82)

The method of claim 82, wherein the non-statin lipid-lowering agent is selected from the group consisting of: ezetimibe, a fibrate, fenofibrate, niacin, an omega-3 fatty acid, and a bile acid resin.

### Claim 84 (depends on 83)

The method of claim 83, wherein the non-statin lipid-lowering agent is ezetimibe or fenofibrate.

### Claim 85 (depends on 79)

The method of claim 79, wherein the antibody or antigen binding protein is administered subcutaneously.

### Claim 86 (depends on 79)

The method of claim 79, wherein the subject is not on a non-statin lipid-lowering agent before and/or during administration of the antibody or antigen-binding fragment thereof.

### Claim 87 (depends on 79)

The method of claim 79, wherein the subject has a form of hypercholesterolemia that is not Familial Hypercholesterolemia (nonFH).

### Claim 88 (depends on 79)

The method of claim 79, wherein the subject has heterozygous Familial Hypercholesterolemia (heFH).

### Claim 89 (depends on 88)

The method of claim 88, wherein the diagnosis of heFH is made either by genotyping or clinical criteria.

### Claim 90 (depends on 89)

The method of claim 89, wherein the clinical criteria is either the Simon Broome Register Diagnostic Criteria for Heterozygous Familial Hypercholesterolemia, or the WHO/Dutch Lipid Network criteria with a score >8.

### Claim 91 (depends on 79)

The method of claim 79, further comprising the step of (c) administering to the subject one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the subject after step (b) is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the subject after step (b) is greater than or equal to 70 mg/dL.

### Claim 92 (depends on 79)

The method of claim 79, further comprising the step of measuring the LDL-C of the subject after step (a) and before step (b).

### Claim 93 (depends on 92)

The method of claim 92, wherein the LDL-C of the subject is measured just prior to the next scheduled dose of the antibody or antigen-binding fragment thereof.

### Claim 94 (depends on 91)

The method of claim 91, further comprising the step of measuring the LDL-C of the subject after step (b) and before step (c).

### Claim 95 (depends on 94)

The method of claim 94, wherein the LDL-C of the subject is measured just prior to the next scheduled dose of the antibody or antigen-binding fragment thereof.
